Compare Vanguard Dividend Appreciation Index Fund ETF (VIG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Dividend Appreciation Index Fund ETF vs Zoetis Inc — how do they compare? Vanguard Dividend Appreciation Index Fund ETF trades at $246.05, while Zoetis Inc trades at $73.82 (market cap $30.39B). The key difference: Zoetis Inc pays a 2.88% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none, and Vanguard Dividend Appreciation Index Fund ETF is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| VIG | ZTS | |
|---|---|---|
52-Week High | $246.19 | $156.76 |
52-Week Low | $209.02 | $71.91 |
Market Cap | — | $30.39B |
Sector | — | Health |
Enterprise Value | — | $37.95B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VIG trades at $246.19, up 0.16% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The ETF focuses on dividend growth stocks, with a 1.5% yield and a 20-year streak of dividend increases. Recent news highlights its role in retirement income strategies and comparisons with peers like SCHD.
The outlook remains positive for long-term investors seeking dividend growth and lower risk, though high RSI suggests near-term consolidation. Risks include market volatility and interest rate sensitivity, but institutional interest and a quality stock selection process support its defensive appeal.
Zoetis (ZTS) trades at $73.4, down 1.95% on the day, as technical indicators signal a bearish trend amid recent price weakness. Fundamentally, the company reported Q2 2026 EPS of $1.87, beating estimates, but revenue was flat and full-year guidance was cut due to softer pet healthcare demand. Analyst sentiment remains mixed with a consensus price target of $94.90, though recent news highlights competitive pressures and a securities class action lawsuit.
The stock presents a value opportunity given its attractive P/E of 12.29 and strong profitability margins, but near-term headwinds from U.S. companion-animal market challenges and legal overhangs pose risks. Upside depends on execution against revised 2026 targets and stabilization in core markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
